PERSPECTA

News from every angle

← Back to headlines

AstraZeneca Licenses Lung Cancer Drug from China's Dizal Pharmaceutical for $1.5 Billion

AstraZeneca has entered into a $1.5 billion licensing agreement with China's Dizal Pharmaceutical for a lung cancer drug. This deal expands AstraZeneca's oncology portfolio with a new therapeutic candidate.

PostShare

Sources

Showing 0 of 2 sources

No articles available in your preferred languages.

2 articles available in other languages below.

seeking-alphaDanish25d ago

AstraZeneca inks $1.5B license deal for lung cancer drug

Read full article →
YahooSpanish25d ago

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

Read full article →

Coverage Timeline

First report: Yahoo · 14 Jul, 06:19Full coverage: 2 · 2hWindow: 2h
Left-leaningCenterRight-leaning
Yahoo14 Jul, 06:19First to report

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

2h later
seeking-alpha14 Jul, 08:13Latest update

AstraZeneca inks $1.5B license deal for lung cancer drug

Related Stories

Investment Potential of Nvidia, Micron, and Broadcom Stocks Examined

18m ago

Stock Market Flashes Dot-Com Bubble Warning Signal

33m ago

Qorvo's $22 Billion Merger Impacts Insider Filings

39m ago

AMD Challenges Nvidia with Bold New Move

46m ago